Access cutting-edge type 1 diabetes (t1d) treatment through this clinical trial at a research site in Miami. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Miami location
Preparing your pre-screening questions…
Access type 1 diabetes (t1d) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related type 1 diabetes (t1d) treatment provided free
Check if you qualify for this type 1 diabetes (t1d) clinical trial in Miami, FL
No-Cost Study Care
Local to Miami
Convenient for FL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety. Visit https://www.polarisstudy.com to learn more!
Sponsor: GentiBio, Inc
Yes, this clinical trial (NCT06919354) has an active research site in Miami, FL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for type 1 diabetes (t1d) treatment options in Miami, FL, this clinical trial (NCT06919354) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Miami research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type 1 diabetes (t1d) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all type 1 diabetes (t1d) clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Miami — not just this study.
Browse Pulmonary Embolism Trials in Miami →